ArticleDiscover oncology2026
Association of CA12 with calcification in ER+/HER-2 negative breast cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundCalcification in breast cancer is closely associated with ER+/HER2- breast cancer, and identifying key molecular markers is crucial for early diagnosis and treatment.
methodsWe integrated bioinformatics analyses of data from the TCGA and GEO databases with in vitro experiments on MCF-7 and MDA-MB-231 cell lines to explore the role of CA12 in breast cancer calcification.
resultsOur analysis identified 132 calcification-related genes, with CA12 highlighted as a significant biomarker. In vitro experiments showed that osteogenic induction promoted calcific nodule formation in ER-positive MCF-7 cells with concomitant CA12 upregulation, though this increase did not reach statistical significance; notably, ER-negative MDA-MB-231 cells exhibited comparable CA12 upregulation without mineralization. We propose integrating CA12 detection with imaging to boost diagnostic accuracy for early ER+/HER2- breast cancer, enabling timely endocrine therapy and improving prognosis.
conclusionThis study offers new insights for early breast cancer diagnosis and individualized treatment, along with proposing CA12 as a potential biomarker for breast cancer calcification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.